Acute Metabolic Outcomes in Diabetic Patients Hospitalized for COVID-19 (DMD-COV)

NCT07560059 | Completed

• 1 other identifier: DMD-COV
• Study Type: observational
• Target: 201
• Locations: 1 country
• Sites: 1

Brief Summary

Diabetes is a major risk factor for severe COVID-19 and poor clinical outcomes during hospitalization. However, little is known about the medium- and long-term metabolic consequences of COVID-19 in people with diabetes after hospital discharge. The DMD-COV study is a prospective, multicenter observational cohort conducted in Algeria. Its aim is to evaluate the cardio-metabolic outcomes of adult patients with diabetes who were hospitalized for confirmed COVID-19 and survived the acute phase of the infection. Adult patients with type 1 or type 2 diabetes will be included during hospitalization or within 30 days after hospital discharge. Participants will be followed for up to one year after discharge, with scheduled evaluations at baseline, 3 months, 6 months, and 12 months. During follow-up, clinical, biological, and therapeutic data will be collected, including glycemic control (HbA1c), body weight, lipid profile, kidney function, and diabetes treatments. The main outcome is the proportion of patients achieving their individualized HbA1c target at 6 months and 12 months after hospitalization for COVID-19. The results of this study will help to better understand the long-term metabolic impact of COVID-19 in people with diabetes and to improve post-COVID diabetes management.

Conditions

Diabetes Mellitus; COVID-19; Post-Acute COVID-19 Syndrome

Keywords

Diabetes; COVID-19; Post-COVID; Glycemic Control; HbA1c; Cardiometabolic Outcomes; Hospitalized Patients; Prospective Cohort; Algeria; Metabolic Syndrome

Outcome Measures

Primary Outcomes (1)

• Glycemic control after hospitalization for COVID-19

  Proportion of patients achieving their individualized HbA1c target according to international diabetes guidelines.

  6 months and 12 months after hospital discharge

Secondary Outcomes (5)

• Change in HbA1c over follow-up

  Baseline, 3 months, 6 months, and 12 months

• Change in body weight and body mass index

  Baseline, 3 months, 6 months, and 12 months

• Evolution of diabetes treatment

  Up to 12 months after hospital discharge

• Changes in lipid profile and renal function

  Baseline, 6 months, and 12 months

• Factors associated with poor glycemic control after COVID-19

  Up to 12 months after hospital discharge

Study Arms (1)

Diabetic patients hospitalized for COVID-19

Adult patients with type 1 or type 2 diabetes who were hospitalized for confirmed COVID-19 and followed prospectively after hospital discharge to assess cardio-metabolic outcomes over a one-year period.

Other: No intervention (observational study)

Interventions

No intervention (observational study) OTHER

This is a non-interventional observational study. No experimental or therapeutic intervention is assigned as part of the study protocol. All medical care and treatments are provided according to routine clinical practice.

Diabetic patients hospitalized for COVID-19

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients with type 1 or type 2 diabetes who were hospitalized for confirmed COVID-19 and followed after hospital discharge to assess cardio-metabolic outcomes.

You may qualify if:

• Age 18 years or older
• Diagnosis of type 1 or type 2 diabetes mellitus
• Hospitalization for laboratory-confirmed COVID-19
• Signed informed consent

You may not qualify if:

• Age under 18 years
• Absence of diabetes mellitus
• Refusal or inability to provide informed consent

Sponsors & Collaborators

• Algerian Society of Diabetology: lead
• Novo Nordisk A/S: collaborator
• Algerian Society of Internal Medicine: collaborator

Study Sites (1)

Djillali Belkhenchir Public Hospital (formerly Birtraria)

Algiers, El Biar, Algeria

Location

MeSH Terms

Conditions

Diabetes Mellitus; COVID-19; Post-Acute COVID-19 Syndrome; Metabolic Syndrome

Interventions

Observation

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; Post-Infectious Disorders; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Insulin Resistance; Hyperinsulinism

Intervention Hierarchy (Ancestors)

Methods; Investigative Techniques

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 26, 2026
• First Posted: April 30, 2026
• Study Start: January 28, 2021
• Primary Completion: August 24, 2022
• Study Completion: August 24, 2022
• Last Updated: April 30, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

AL (1)